Che-Wen, Tsai, Ph.D.(Candidate.)
Department of Pharmacology, College of Medicine, National Taiwan University, Taipei, Taiwan

The Rise of iPS Cells: From Concept to Clinical Hope

Regenerative medicine is a multidisciplinary field addressing diseases characterized by irreversible tissue loss—conditions that historically relied on organ transplantation. However, transplantation is often stymied by chronic donor shortages, ethical dilemmas, and the risk of immune rejection. Regenerative medicine offers a transformative hierarchy of solutions, ranging from gene therapy and stem cell transplantation to tissue engineering [1].

Early stem cell therapies faced significant hurdles: autologous or allogeneic stem cells often exhibited inconsistent quality and limited expansion capacity [2]. A paradigm shift occurred in 2007 when Shinya Yamanaka’s team successfully reprogrammed human somatic cells into induced pluripotent stem cells (iPSCs) [3]. This breakthrough allowed patient-specific cells to serve as a sustainable, standardized source for cell therapy. Despite this promise, iPSCs carry inherent risks, including high production costs, potential tumorigenicity (teratoma formation), and challenges in achieving high differentiation purity [4]. These factors have created bottlenecks in standardizing iPSC therapies for clinical application, even as the unmet medical needs for neurodegenerative diseases, heart failure, and muscular atrophy accelerate the push for regulatory approval.

The Japanese Milestone and the Shift to “Active Repair”

In December 2025, Japan marked a historic milestone by approving two iPSC-derived products: a cardiomyocyte sheet therapy and a neuronal transplantation therapy. This ended the long wait for commercialized iPSC products since the technology’s inception. For diseases involving irreversible cell loss—such as Parkinson’s disease (PD), multiple sclerosis, and heart failure—traditional pharmacology can only delay degeneration. iPSCs offer a shift from conservative management to  active repair.

In PD, for instance, the death of dopaminergic neurons in the substantia nigra leads to motor dysfunction. By transplanting iPSC-derived dopaminergic precursor neurons into the striatum, clinicians can restore localized dopamine secretion. This approach surpasses traditional drugs by mimicking physiological rhythms and providing long-term effects without daily medication [5]. Furthermore, compared to using embryonic tissues, iPSCs mitigate ethical controversies, reduce immune rejection, and provide a stable cell source. 

Regulatory Challenges 

The path to commercialization is fraught with regulatory obstacles. Primary concerns include:

1. Tumorigenic Risk:  Residual undifferentiated stem cells can form tumors; the use of viral vectors in gene editing may further increase oncogenic risks.
2. Standardization Difficulties:  Unlike chemical compounds, iPSC batches are highly sensitive to culture environments, leading to disparate international standards for safety and purity.
3. Small Sample Sizes:  Prohibitive costs limit clinical trial scales, often resulting in Type II errors or overly wide confidence intervals, making it difficult to statistically confirm stable efficacy [6, 7].

Globally, regulatory stances vary: the EU maintains a stringent pre-approval system; the US offers flexibility through a “pre-notification” system (though this remains subject to evolving federal rulings); and Japan adopts a pragmatic “dual-track” approach [8].

Japan’s Regulatory Framework: ASRM vs. PMD Act

Since 2014, Japan has managed iPSC therapies under two frameworks:

• The Act on the Safety of Regenerative Medicine (ASRM): Focuses on medical institutions. It treats iPSC therapy as a medical procedure (intervention), allowing for rapid, small-scale clinical research and self-funded treatments after reporting to the Ministry of Health, Labour and Welfare (MHLW).
• The Pharmaceuticals and Medical Devices Act (PMD Act): Focuses on biopharmaceutical enterprises. It treats iPSCs as “products” requiring rigorous clinical trials for commercialization [9]. The PMD Act allows for the conditional, time-limited approval of iPSC-derived products. If a product is proven safe and shows probable efficacy, it can enter the market for seven years with medical insurance support. This “probationary” period allows companies to treat patients and collect real-world data, which is required to secure permanent approval later.

While the dual-track system’s flexible management has successfully boosted the number of clinical research applications, significant hurdles remain. There is a persistent “standardization chasm” between research projects governed by the ASRM and those under the PMD Act. Because these frameworks operate on different criteria, data and protocols are often not interchangeable, creating inefficiencies in the field [9]. The PMD Act’s conditional, time-limited approval pathway features a relatively low threshold for entry. This “lenient” approach may lead companies to overestimate the commercial potential of iPS-cell products. If these products fail to meet long-term expectations after hitting the market, it could result in substantial financial losses for investors and developers alike [10].

The Role of Regulatory Guidelines and Technical Guidance

Beyond “hard” legislation, regulatory agencies issue detailed guidelines and technical guidance that play a crucial role in iPSC clinical development. These cover aspects such as trial design, data privacy, and manufacturing processes.

• Risk Mitigation: Unlike conventional drugs, regenerative products carry unique risks like tumorigenicity due to insufficient cell purity. In response, Japanese regulators have issued specific guidance on genomic stability and cell purity assays to strictly monitor oncogenicity.
• Accelerating Approval: While these guidelines are not always legally mandatory, enterprises strictly adhere to them to expedite the review process.
• Bridging the Gap: These guidelines intervene early in clinical research (under ASRM), ensuring that early-stage trial designs align with the rigorous quality standards required for eventual commercialization (under the PMD Act). By clarifying the “key data” required for final review, these rules prevent companies from misjudging a product’s clinical potential, thereby reducing unnecessary investment risks [8, 9].

Toward a Global Consensus

The future of iPSC therapy transcends national borders. The experience gained by pioneers like Japan in managing iPSC clinical research and trials can significantly accelerate the progress of developing nations in this field. By operating under a unified set of standards and frameworks, these emerging countries can contribute a massive influx of clinical data. This data, in turn, helps address the issue of small sample sizes often found in pioneer nations’ studies. Particularly developing countries like China—are seeing an explosion in clinical trials, backed by massive patient cohorts and state funding [11]. This creates a powerful positive feedback loop that drives the entire field of regenerative medicine forward.

Currently, global regulations resemble “isolated islands.” Establishing international standards—such as unified purity assays and tumorigenicity benchmarks—is essential to achieve data interchangeability. By harmonizing regulatory consensus, we can avoid redundant trials and significantly shorten the time-to-market. When data is shared and validated under a global framework, iPSC therapy will evolve from an expensive “bespoke science” into a standardized global industry, providing accessible, life-changing solutions for millions of patients suffering from organ failure and neurodegeneration.

Reference

1.         Sampogna, G., S.Y. Guraya, and A. Forgione, Regenerative medicine: Historical roots and potential strategies in modern medicine. J Microsc Ultrastruct, 2015. 3(3): p. 101-107.

2.         Yamanaka, S., Pluripotent Stem Cell-Based Cell Therapy-Promise and Challenges. Cell Stem Cell, 2020. 27(4): p. 523-531.

3.         Takahashi, K., et al., Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell, 2007. 131(5): p. 861-72.

4.         Dhaiban, S., et al., Clinical translation of human iPSC technologies: advances, safety concerns, and future directions. Front Cell Dev Biol, 2025. 13: p. 1627149.

5.         Sawamoto, N., et al., Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinson’s disease. Nature, 2025. 641(8064): p. 971-977.

6.         Hamad, A.A. and S.K. Ahmed, Understanding the Lower and Upper Limits of Sample Sizes in Clinical Research.Cureus, 2025. 17(1): p. e76724.

7.         Neofytou, E., et al., Hurdles to clinical translation of human induced pluripotent stem cells. J Clin Invest, 2015. 125(7): p. 2551-7.

8.         Song, S.J., et al., Comparative analysis of regulations and studies on stem cell therapies: focusing on induced pluripotent stem cell (iPSC)-based treatments. Stem Cell Res Ther, 2024. 15(1): p. 447.

9.         Choi, K.N. and W.B. Liu, Driving the future of iPS-cell-based therapy in Japan: government strategies, regulatory review and clinical development. Drug Discov Today, 2026. 31(1): p. 104562.

10.       Hakariya, H., et al., Japan’s Conditional/Time-Limited Early Approval System in Regenerative Medicine: A Case Study of Rise and Falls of Autologous Skeletal Myoblast Sheets. Clin Pharmacol Ther, 2025. 117(5): p. 1171-1174.